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Background: In this study we aimed to quantify tumor suppressor gene (TSG) promoter methylation densities
levels in primary neuroblastoma tumors and cell lines. A subset of these TSGs is associated with a CpG island
methylator phenotype (CIMP) in other tumor types.
Methods: The study panel consisted of 38 primary tumors, 7 established cell lines and 4 healthy references.
Promoter methylation was determined by bisulphate Pyrosequencing for 14 TSGs; and LINE-1 repeat element
methylation was used as an indicator of global methylation levels.
Results: Overall mean TSG Z-scores were significantly increased in cases with adverse outcome, but were unrelated
to global LINE-1 methylation. CIMP with hypermethylation of three or more gene promoters was observed in 6/38
tumors and 7/7 cell lines. Hypermethylation of one or more TSG (comprising TSGs BLU, CASP8, DCR2, CDH1, RASSF1A
and RASSF2) was evident in 30/38 tumors. By contrast only very low levels of promoter methylation were recorded
for APC, DAPK1, NORE1A, P14, P16, TP73, PTEN and RARB. Similar involvements of methylation instability were
revealed between cell line models and neuroblastoma tumors. Separate analysis of two proposed CASP8 regulatory
regions revealed frequent and significant involvement of CpG sites between exon 4 and 5, but modest involvement
of the exon 1 region.
Conclusions/significance: The results highlight the involvement of TSG methylation instability in neuroblastoma
tumors and cell lines using quantitative methods, support the use of DNA methylation analyses as a prognostic tool
for this tumor type, and underscore the relevance of developing demethylating therapies for its treatment.
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Neuroblastomas and ganglioneuromas are childhood
tumors of the sympathetic nervous system that develop
from primitive, neural crest-derived cells similar to
those of the adrenal medulla and the sympathetic ganglia
[1-3]. Afflicted patients present highly variable clinical
courses, with spontaneous regression or critical tumor
progression as two extreme and contrasting outcomes [2].
A number of clinical features and tumor phenotypes influ-
ence the disease outcome; the most important are age at
diagnosis, tumor stage, amplification of the MYCN* Correspondence: Catharina.Larsson@ki.se
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reproduction in any medium, provided the oroncogene, activating ALK mutations, and somatic loss
within chromosomal region 1p [1,2,4-8]. More recently,
hypermethylation of tumor suppressor gene promoters
were shown to be frequent in neuroblastoma with possible
prognostic implications [9,10].
DNA methylation most commonly refers to methylation
of the C in a CpG dinucleotide motif; a modification of
fundamental importance for epigenetic regulation [11]. In
normal cells, DNA methylation is central in processes
such as expressional regulation, parental imprinting, and
X-chromosome inactivation in females [11]. Abundant
CpG methylation in promoter regions is widely associated
with epigenetic silencing of gene transcription [11]. Aber-
rant DNA methylation is increasingly observed in various
diseases. In cancer, promoter hypermethylation may be an. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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silencing, which is otherwise associated with genetic
mechanisms like mutation and deletion [12-14]. Indeed,
concerted anomalous hypermethylation of TSG promoters
is reported in an increasing number of cancer types, in-
cluding among others neuroblastomas [10,15-18], and has
been termed CpG island methylator phenotype (CIMP)
[19]. Several reports indicate an association between the
CIMP phenotype, advanced tumor disease and adverse
outcome [15,16]. However, it is presently unknown
whether increasing TSG hypermethylation is selected for
during progression [16], or if aberrant DNA hypermethy-
lation triggered by unknown factors confer epigenetic
changes responsible for tumor progression.
The present view holds that cancer cells carry localized
promoter hypermethylation together with global hypo-
methylation [20]. The LINE-1 group of retrotransposon ele-
ments comprises approximately 17% of the human
genome [21] and has been used as an analogue for
genome-wide DNA methylation levels [21-26]. The LINE-
1 retrotransposon promoter element is frequently hypo-
methylated in cancers [24,26]. The relationship between
CIMP and LINE-1 methylation is presently unknown,
however a recent study suggested that LINE-1 hypo-
methylation is inversely correlated with CIMP in colorec-
tal cancer [27].Table 1 Overview of methylation levels in normals and prima
No. of Normals (% met) Hypermet
CpGs mean range cut-off (%
Genes with detected hypermethylation
BLU 8 4 (3-4) >1
CASP8 - A1 4 1 (0-3) >1
CASP8 - A2 5 36 (24-41) >5
DCR2 9 18 (10-21) >3
CDH1 9 4 (4-5) >1
RASSF1A 5 13 (8-21) >3
RASSF2 6 6 (4-8) >1
Genes without detected hypermethylation
APC 10 2 (1-4) >1
DAPK1 13 1 (0-1) >1
NORE1A* 13 1 (1-3) >1
P14 13 5 (2-11) >1
P16 4 1 (0-1) >1
TP73 19 1 (1-2) >1
PTEN 10 1 (1-1) >1
RARB 10 6 (5-7) >1
Global methylation
LINE-1 multiple 67.7 (65.6-70.3) -
NB = Neuroblastoma; Gang = Ganglioneuroma.
* previously published in [32]. (Geli et al. 2008).While several studies have assessed gene methylation in
neuroblastomas, the methods employed were nonquanti-
tative [9,10,28,29]. The present study was undertaken to
quantitatively assess alterations of CpG methylation glo-
bally and in 14 prominent TSG promoters in relation to
pathologic phenotypes in neuroblastomas.
Results
Hypermethylation of BLU, CASP8, DCR2, CDH1, RASSF1A
and RASSF2 in neuroblastoma tumors and cell lines
CpG methylation status was assessed for regulatory
regions of 14 tumor suppressor genes in 38 tumors and 4
healthy adrenal medullary reference samples (Table 1). For
CASP8 two alternative regulatory regions were analyzed,
referred to as CASP8 A1 and CASP8 A2, and based on
the findings CASP8 A1 was selected for the further ana-
lyzes. Several of the investigated TSGs have chromosomal
locations that are recurrently lost in neuroblastoma
[30,31]: TP73 on 1p, BLU, RARB and RASSF1A on 3p,
and PTEN on 10q. Epigenetic silencing of these genes
would account for the second hit in Knudson’s 2-hit hy-
pothesis. As expected, the majority of genes showed negli-
gible or very low mean levels of methylation (below 10%)
in the reference samples, and the cut-off for hypermethy-
lation was therefore set to >10% (Table 1). DCR2,
RASSF1A and CASP8A2 displayed higher levels ofry tumors
hylation Tumors (% met) Tumors > cut-off
met) mean range NB Gang
0 7 (2-65) 4 0
0 16 (0-52) 21 0
0 42 (15-64) 9 0
0 12 (0-67) 5 0
0 3 (1-12) 1 0
0 43 (1-89) 23 0
0 6 (3-11) 1 0
0 1 (0-2) 0 0
0 0 (0-1) 0 0
0 1 (0-3) 0 0
0 1 (0-3) 0 0
0 0 (0-1) 0 0
0 1 (0-2) 0 0
0 1 (0-1) 0 0
0 2 (0-5) 0 0
64.1 (53.9-74.8)
Table 2 Methylation levels in neuroblastoma cell lines compared to primary tumors
Sample APC BLU CASP8- CASP8- DAPK DCR2 CDH1 NORE1A P14 P16 TP73 PTEN RARB RASSF1A RASSF2
group (% met) (%) A1 (%) A2 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
Cut-off
Hypermethylation >10 >10 >10 >50 >10 >30 >10 >10 >10 >10 >10 >10 >10 >30 >10
NB Cell lines
IMR-32 2 6 77 81 0 80 9 3 5 0 1 1 - 93 6
SH-5YSY 1 36 89 85 0 88 19 2 1 1 1 1 - 94 11
SK-N-AS 1 - 0 77 0 81 6 3 2 0 5 1 - 94 26
SK-N-BE - - 94 - - 78 - - - 1 - 0 - 95 -
SK-N-DZ 3 - 42 39 1 37 12 6 3 1 3 1 4 92 6
SK-N-F1 1 - 50 72 0 76 10 1 2 1 2 1 8 95 10
SK-N-SH 0 - 78 80 0 86 8 2 - 1 1 1 3 93 8
All 1 21 61 73 0 75 11 3 3 1 2 1 5 94 11
NB Tumors
All 1 7 16 42 0 12 3 1 1 0 1 1 2 43 6
Number > cut-off n = 0 n = 4 n = 21 n = 9 n = 0 n = 4 n = 1 n = 0 n = 0 n = 0 n = 0 n = 0 n = 0 n = 23 n = 1
met = methylation; Bold indicate hypermethylation.
Figure 1 Comparison of mean TSG Z-scores between primary
tumors (filled diamonds), and reference adrenal medullas (open
diamonds).
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http://www.biomedcentral.com/1471-2350/13/83intrinsic methylation in reference samples, and conse-
quently cut-offs for hypermethylation were set at 30%,
30% and 50% respectively. In the tumor panel, increased
promoter methylation was observed in BLU, CASP8,
DCR2, CDH1, RASSF1A and RASSF2 (Table 1), possibly
providing the second hit for BLU, RARB and RASSF1A.
An increase in methylation compared to reference sam-
ples was especially prominent in RASSF1A (> 60% of the
tumors) and CASP8 A1 (> 50% of the tumors). By contrast
hypermethylation was not observed for APC, DAPK1,
NORE1A, P14, P16,TP73, PTEN or RARB (Table 1).
In the seven neuroblastoma cell-lines analyzed hyper-
methylation was present in BLU, CASP8, DCR2, CDH1,
RASSF1A and RASSF2, but was not observed for APC,
DAPK1, NORE1A, P14, P16, TP73, PTEN or RARB
(Table 2). Hence, the overall methylation pattern in cell
lines mirrored that in tumors, i.e. genes that were highly
methylated in cell lines also featured hypermethylation
in primary tumors (Table 2).
For comparison of methylation densities Z-scores were
calculated for each TSG as well as a mean for all TSG
analyzed. Taking the whole tumor population into ac-
count there was no apparent statistically significant dif-
ference between tumors and references with regards to
mean Z-scores (Figure 1).
Hypermethylation above the cut-off range was evident
for one or more TSG promoters in 30 of the 38 tumors.
Additional file 1: Table S1 and Additional file 2: Table S2
details the results for each TSG in the 38 individual
tumors concerning mean methylation density of all CpG
sites as well as the range of minimum to maximum values
for the individual CpGs recorded. In all cases geneswithout detected hypermethylation exhibited mean values
below the cut-off at 10%. With one single exception the
maximum values recorded for any individual CpG were
also below the cut-off at <10% (Additional file 2: Table S2).
These observations suggest that the APC, DAPK1,
NORE1A, P14, P16, TP73, PTEN and RARB promoters are
rarely methylated in neuroblastomas. Six genes showed
promoter hypermethylation in primary tumors, and in
addition, for some samples increased methylation was
recorded at individual CpGs although the mean of all CpGs
did not reach above the cut-off (Additioanal file 1: Table S1;
Figures 2 and 3). BLU exhibited mean methylation >10%
cut-off in 4 tumors and maximum methylation up to 22%
in 10 additional tumors. Corresponding results were, for
CDH1 (1 tumor with mean >10% and 1 additional tumor
with max at 17%), for RASSF2 (1 tumor+24 tumors up to
Figure 2 Hypermethylation of promoter regions for BLU, DCR2, CDH1, RASSF2 and RASSF1A in primary tumors. The scatterplots illustrate
the distribution of methylation densities detected at each CpG analyzed in the individual tumors. Filled diamonds represent tumors with
hypermethylation (the mean value for all CpGs of the gene are above cut-off), while tumors without hypermethylation are indicated as open
diamonds. The cut-off levels for hypermethylation are marked by a dotted line for BLU (>10 %), CDH1 (>10 %), RASSF2 (>10 %), DCR2 (>30 %), and
RASSF1A (>30 %).
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RASSF1A (23 tumors +1 up to 31%), and for CASP8 A1
(21 tumors+ 2 tumors up to 21%). BLU, CDH1, RASSF2,
DCR2 and RASSF1A showed quite similar dispersal in
methylation densities between individual CpGs (Figure 2).
However for CASP8 A1 a gradient of increased methylation
was noted from CpG 1 to 2, 3, and 4 (Figure 3). Similarly,
CASP8 A2 showed the highest methylation at CpG 2, 3
and 5, moderate methylation at CpG 4 and the lowest levels
at CpG 1 (Figure 3).
CIMP phenotype in neuroblastoma tumors and cell lines
CIMP was here defined as tumors with concerted hyper-
methylation in 3 or more of the assessed TSGs in agree-
ment with our previous definitions of this phenotype
[32]. Six neuroblastomas, but no ganglioneuromas
showed hypermethylation of 3 or 4 genes and thus met
the criteria for CIMP (tumors 14, 18, 19, 20, 27 and 35;
Table 3). All genes involved in hypermethylation in thisstudy contributed to CIMP, and mean Z-scores and
DCR2 Z-scores were significantly higher in tumors clas-
sified as CIMP (p = <0.003). Similarly, all 7 cell-lines car-
ried promoter hypermethylation for 3 to 6 genes in
agreement with a CIMP phenotype (Table 2).
Analyses of alternative regulatory regions in CASP8
The two reported regulatory regions of CASP8 are illu-
strated in Figure 4, together with the location of primers
applied in previous and the present study. In this study,
the mean methylation levels for CASP8 A2 were found to
be high, between 15-64%, but this was mirrored by prom-
inent methylation also in the reference samples (24-41%).
Nine tumors reached a methylation level above the 50%
cut-off level. In 8 of these 9 tumors hypermethylation
was also observed for the CASP8 A1 region (Table 3).
For CASP8 A1 methylation levels in reference adrenal
medullas were low <10%, while hypermethylation above
the cut-off was recorded in 21 tumors (Table 3).
Figure 3 CpG hypermethylation at the two reported regulatory regions of the CASP8 gene. Methylation densities detected at the CpGs
assayed in the respective locations CASP8 A1 and CASP8 A2 are shown at the top, where filled diamonds represent hypermethylated tumors and
open diamonds indicate unmethylated tumors. The cut-off levels >10 % for CASP8 A1 and >50 % for CASP8 A2 are marked by dotted lines. The
diagram at the bottom illustrates the relationship between mean methylation levels of CASP8 A1 (filled staples) and CASP8 A2 (open staples) in all
samples analyzed including tumors, references and cell lines.
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genetic features
Mean TSG Z-scores were significantly higher in tumors
from patients with adverse outcome at follow-up i.e.patients who died of disease (DOD) or were alive with
disease (AWD) vs. cases with no evidence of disease
(NED) (Kruskal-Wallis p = 0.04; Figures 5 and 6). Mean
TSG Z-score, CASP8 A1 Z-score and RASSF1A Z-score
Table 3 Results for dysmethylated promoter regions in primary tumors
Case Primary tumor High-risk Follow BLU Casp8 A1 CASP8 A2 DCR2 CDH1 RASSF1A RASSF2 Total CIMP Z-score LINE-1
no. type stage MYCN therapy up >10% >10% >50% >30% >10% >30% >10% no. all genes %
1 NB 4S - - NED - CASP8 A1 + CASP8 A2 - - RASSF1A - 2 - - 0.30 64.8
2 NB 1 - - NED - CASP8 A1 + CASP8 A2 - - RASSF1A - 2 - 0.23 66.3
3 NB 3 - - NED - CASP8 A1 - - - RASSF1A - 2 - - 0.04 58.0
4 NB 1 - - NED - - - DCR2 - - - 1 - 0.07 65.8
5 NB 4 yes yes DOD - - - - - - - - - - 0.11 68.2
6 NB 2A - - NED - CASP8 A1 - - - RASSF1A - 2 - - 0.33 55.7
7 NB 4 yes yes DOD - CASP8 A1 - - - - - 1 - 0.26 70.0
8 NB 2 - - NED - - - - - RASSF1A - 1 - - 0.65 58.2
9 NB 4 yes yes DOD - CASP8 A1 + CASP8 A2 - - - - 1 - - 0.06 69.8
10 NB 4S - - NED - - - - - - - - - - 0.37 62.9
11 NB 4 yes yes NED - CASP8 A1 + CASP8 A2 - - - - 1 - - 0.06 66.4
12 NB 4 yes yes DOD BLU - - - - RASSF1A - 2 - 0.57 62.4
13 Gang - - - NED - - - - - - - - - - 0.55 68.9
14 NB 3 yes yes NED - - - DCR2 - RASSF1A RASSF2 3 CIMP 1.19 57.0
15 Gang - - - NED - - - - - - - - - - 0.58 72.6
16 NB 4 yes yes NED - - - - - - - - - - 0.52 67.2
17 NB 2 - - NED - - - - - RASSF1A - 1 - - 0.14 57.1
18 NB 4 - - NED - CASP8 A1 - DCR2 - RASSF1A - 3 CIMP 0.24 69.9
19 NB 3 - - NED - CASP8 A1 - DCR2 - RASSF1A - 3 CIMP 0.55 59.7
20 NB 2 - - AWD - CASP8 A1 - DCR2 CDH1 RASSF1A - 4 CIMP 1.87 60.2
21 NB 4 yes yes NED - CASP8 A1 + CASP8 A2 - - - - 1 - - 0.30 66.8
22 NB 2 - - NED - CASP8 A1 - - - RASSF1A - 2 - 0.21 55.6
23 NB 3 yes yes NED BLU - CASP8 A2 - - - - 2 - - 0.32 65.9
24 NB 3 - - NED - CASP8 A1 + CASP8 A2 - - RASSF1A - 2 - 0.01 53.9
25 Gang - - - NED - - - - - - - - - . 0.62 65.9
26 NB 3 - - NED - CASP8 A1 + CASP8 A2 - - - - 2 - - 0.25 59.7
27 NB 4 yes yes DOD BLU CASP8 A1 - - - RASSF1A - 3 CIMP 1.57 65.9
28 NB 4S - - NED - CASP8 A1 - - - RASSF1A - 2 - 0.11 58.7
29 NB 3 - - DOC - CASP8 A1 + CASP8 A2 - - RASSF1A - 2 - 0.14 55.0
30 NB 1 - - DOC - - - - - RASSF1A - 1 - - 0.57 61.7
31 NB 1 - - NED - - - - - - - - - - 0.43 74.8
32 NB 2 - - DOD - CASP8 A1 - - - RASSF1A - 2 - 0.10 64.4
33 NB 1 - - NED - - - - - RASSF1A - 1 - - 0.28 67.7
34 NB 4 - - NED - - - - - - - - - - 0.29 71.5
35 NB 1 - - NED BLU CASP8 A1 - - - RASSF1A - 3 CIMP - 0.20 67.9
36 NB 1 - - NED - CASP8 A1 - - - RASSF1A - 2 - - 0.17 66.7
37 NB 3 yes yes NED - - - - - RASSF1A - 1 - 0.48 66.0
38 NB 3 - - NED - CASP8 A1 - - - RASSF1A - 2 - - 0.10 67.7
NB = neuroblastoma; AWD 0 Alive with disease; DOD = Dead of disease, NED = No evidence of disease; DOC = Dead of surgical complications.
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ganglioneuromas (Mann–Whitney U Test p-values =0.025,
0.014, <0.009 respectively).
As expected significant associations were apparent be-
tween tumor stage vs. MYCN amplification; vs. 1p loss;
and vs. high-risk, as well as between MYCN amplifica-
tion vs. 1p loss and vs. high risk. High-risk was alsosignificantly correlated to poor outcome. The strong cor-
relation between these features support the representa-
tivity and relevance of the material under study.
Global LINE-1 methylation
Methylation density of LINE-1 repeat elements was
determined as a measure of the global methylation
Figure 4 Methylation analyzes of the two reported regulatory regions of the CASP8 gene. The location of CASP8 A1 [25] and CASP8 A2 [27]
are indicated in the schematic illustration of the CASP8 gene locus. Location of MSP primers applied by Teitz et al., and Banelli et al., are indicated in colour
in the sequences shown. The locations of primers used in the present study are marked in bold and the sequence is underlined.
Figure 5 Association between Z-score and patient outcome at
follow-up. Box-plots illustrate mean TSG Z-scores in patients with
different outcome at follow-up; no evidence of disease (NED), dead
of disease (DOD), alive with disease (AWD), or dead of surgical
complications (DOC).
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tion were recorded in reference samples and primary
tumors, while the levels were lower in neuroblastoma
cell lines (Figure 7). LINE-1 Z-scores were not signifi-
cantly different between tumors and reference adrenal
medulla. There was a negative correlation between
LINE-1 and RASSF1A Z-scores (Spearman Rank Order
Correlation −0.56; p < 0.05). Stage 4 neuroblastomas
showed higher LINE-1 methylation vs. lower stage
tumors (Mann–Whitney U Test; p = 0.01; Figure 7).
LINE-1 methylation was not correlated to CIMP or
other tumor features.
Discussion
In the current study we used quantitative bisulfite Pyro-
sequencing to assess promoter methylation levels of
tumor suppressor genes known to be frequently hyper-
methylated in cancer. In 30/38 tumors we found signifi-
cant hypermethylation in one or more of the following
genes; BLU, CASP8, DCR2, CDH1, RASSF1A and
RASSF2. Overall Z-scores for the TSGs assessed were
significantly associated with adverse outcome. Further-
more, six of the 38 tumors conformed to the criteria for
CIMP, i.e. CpG island methylator phenotype. The non-
Figure 7 Global methylation levels of LINE-1 repeats in the
different sample groups, and association between LINE-1 and
tumor stage. Box-plots at the top show Z-scores for LINE-1
repeat elements in primary tumors, reference adrenal medullas
and neuroblastoma cell lines. Box-plots below illustrate relatively
higher LINE-1 Z-scores in Stage 4 as compared to Stage 1, 2, 3 and
4 S tumors.
Figure 6 Kaplan-Meier plots illustrating survival in patients
with an average Z-score higher or lower than the median of
the Z-scores for all methylated TSGs (Table 3). There is a
significant difference between the two groups (p =<0.04), indicating
adverse outcome in the group with increased mean Z-scores.
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sents the closest possible healthy analogue to the cells
that comprise neuroblastomas. Neuroblastomas arise
solely in neural crest-derived cells of sympathoadrenal
lineage ([33] and others), the very cells that would form
the adrenal medulla (and abdominal sympathetic gan-
glia) in healthy individuals [3]. In this current study they
were only used to confirm that TSG methylation is low
in healthy tissue, and to determine suitable cut-off levels
for different TSGs. The level of cut-off for hypermethy-
lation in individual genes was set conservatively to ex-
ceed the methylation density observed in the reference
adrenal medulla (Table 1). For genes where no methyla-
tion was observed the cut-off was set to 10% to avoid
false positives resulting from background fluctuation.
For the genes where methylation was detected in refer-
ence adrenal medulla (CASP8A2, DCR2, RASSF1A) the
cut-off in tumors was set well above the level observed
in the reference samples (Table 1). Other recent publica-
tions on DNA hypermethylation in neuroblastoma either
do not utilize reference controls [9,10], or compare to
“normal adrenal” and blood lymphocyte DNA [34]. We
used the reference tissue only to assess presence or ab-
sence of hypermethylation; for the comparison between
methylation levels and clinical/genetic phenotypes, we
took into account Z-scores for all 38 tumors in the
series, independent of whether they were classified as
hypermethylated or not. Hence, methylation levels in
reference adrenal medullary material were not included
in any statistical calculation.
Although several recent studies have assessed methyla-
tion in genes with putative tumor suppressor properties[9,10], this current study is the first to employ a quanti-
tative method, pyrosequencing, to assess promoter
methylation in multiple TSGs. Our data partially corrob-
orate the findings of Grau et al. and Hoebeeck et al., as
we find abundant methylation in CASP8A and RASSF1A;
however, we did not observe significant hypermethyla-
tion in the PTEN promoter as reported by Hoebeeck
et al. We here acknowledge the sensitivity of methyla-
tion specific PCR (MSP) in detecting low levels of
methylation. However, this highly sensitive, nonquantita-
tive assay is known to produce false positive results
[35,36]. Further, the biological significance of methyla-
tion detected by MSP may be limited, as the technique
is capable of producing positive results down to a
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This corresponds to a very limited subset of cancerous
cells in a tumor, and may in fact represent DNA methy-
lation in contaminating cell types. This underscores the
importance of employing quantitative methods when
assessing DNA methylation – whenever possible com-
bined with relevant reference samples for the sake of
arbitration.
CASP8, defined as a tumor suppressor gene by Teitz
et al. [28], promotes apoptosis upon activation of the Fas
apoptotic pathway through the Fas ligand [37]. There has
been some debate concerning the localization of the CASP8
regulatory region. In 2000 Teitz et al. reported agreement
between methylation of a CpG-rich region (defined by Gen-
Bank accession number AF210257, positions 536–856;
Figure 4) and absent CASP8 expression in neuroblastomas.
Also, the region was reported to be methylated almost ex-
clusively in neuroblastomas with MYCN amplification.
Teitz et al. indicated that this could signify that inactivation
of the Fas apoptotic pathway is needed for the survival of
neuroblastoma cells expressing high levels of MYCN. A
contrasting view was presented by Banelli et al. who did
not find correlation between CASP8 silencing and MYCN
amplification, although higher frequencies of methylation
were detected in MYCN-amplified cells [29]. They also
argued that the CpG-rich intragenic region assessed by
Teitz et al. is not a true regulatory region for CASP8. In-
stead, a region flanking exon 1 was proposed as the CASP8
promoter (Figure 4). In the current paper we have assessed
the regulatory regions suggested in both publications,
designated as CASP8 A1 [28] and CASP8 A2 [29] (Figure 4).
Furthermore, we have compared the methylation levels in
these sites in neuroblastomas to those of healthy reference
tissues, which was not undertaken in the previous studies.
The differences observed between methylation of the
regions CASP8 A1 and CASP8 A2 in reference adrenal me-
dullary DNA are striking: the region CASP8 A1, while
abundantly methylated in neuroblastomas (mean methyla-
tion 16.2%; 21 tumors over cut-off), was devoid of methyla-
tion in reference adrenal medulla. In contrast, CASP8 A2
had a high degree of methylation in both tumors and refer-
ences(9 tumors over cut-off; mean methylation in tumors
42% vs. 36% in reference samples). Thus, hypermethylation
at CASP8 A1 was found as a better indicator of a patho-
logic condition than high methylation at the CASP8 A2 re-
gion. Furthermore, CASP8 A1 and CASP8 A2 both showed
striking variations in methylation densities between individ-
ual CpGs (Figure 3). For CASP8 A1 a gradient with increas-
ing methylation from CpG 1 to CpG 4 was noted, while for
CASP8 A2 very high methylation was frequently recorded
at CpG 2, 3 and 5 (Figure 3). These observations underline
the importance of analyzing more than single CpGs as an
indicator of methylation density.A long-standing dilemma in neuroblastoma research is
the proposed association between CASP8 methylation
and MYCN amplification [9,10,28,38]. Like Grau et al.
we do not find a correlation between CASP8 A1 methy-
lation and MYCN amplification [10]. In contrast,
Hoebeeck et al., who also assessed the CASP8 A1 region,
performed a meta-analysis including a total of 115
neuroblastomas that linked methylation of the CASP8
A1 region with MYCN-amplification [9]. However, the
included studies utilized non-quantitative MSP [9,28,38].
Our findings provide an epigenetic explanation to a pre-
vious study wherein loss of CASP8 protein expression
was observed in a majority of neuroblastomas [39]. We
further support, backed by quantitative epigenetic data,
the observation from that study that no correlation
exists between loss of CASP8 and adverse neuroblast-
oma features and outcomes (such as MYCN amplifica-
tion and reduced survival) [39].
The CpG Island Methylator Phenotype, CIMP, is char-
acterized by concerted abnormal hypermethylation in
CpG rich gene promoters. Such epigenetic remodeling
could lead to the simultaneous inactivation of cellular
functions that regulate growth, differentiation and apop-
tosis and thus contribute to neoplasia development and
disease phenotype. Indeed, CIMP has been described in
a number of cancers, including neuroblastomas, often
in conjunction with unfavorable disease progression
[15,16]. Abe et al. defined CIMP as simultaneous methy-
lation in CpG islands of the PCDHB and PCDHA gene
families, and the HLP, DKFZp451I127 and CYP26C1
genes, and found this genotype associated to MYCN
amplification [17,18]. In the current study CIMP was
observed in 6/38 tumors and in 7/7 cell lines. However,
no significant correlations between CIMP and clinical/
genetic features were observed. These results support
that concerted promoter hypermethylation is an import-
ant facet of the neuroblastoma causality, however if
hypermethylation of key TSGs are involved in fatal dis-
ease progression they would partly differ from those
assessed in this study. By contrast, significantly higher
mean TSG Z-scores were observed in tumors with poor
outcome at follow-up, which further indicates that
hypermethylation is a component of morbidity in neuro-
blastomas. Analysis of a subset of TSG promoters is
likely to render a somewhat fragmental insight into the
role of promoter hypermethylation in neuroblastoma
development. More global approaches such as methyla-
tion arrays are likely to yield a more detailed account of
the key genes which, by undergoing hypermethylation,
significantly impact tumor progression.
LINE-1 is frequently hypomethylated in cancer [24,26],
leading to its activation – which in turn causes genomic
instability [40]. In the current study LINE-1 Z-scores
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stage 1, 2, 3, and 4 S, indicating global hypermethylation.
The finding indicates that genomic instability in meta-
static neuroblastomas is not caused by LINE-1 activa-
tion. Taking into consideration that DNA methylation is
a disseminative event, this finding contributes to an
emerging picture of aberrant epigenetic patterning in
deleterious neuroblastomas.
Several TSGs showed prominent promoter hyper-
methylation in this study. The two most notably methy-
lated TSG promoters were CASP8 A1 and RASSF1A.
Furthermore BLU and DCR2 also exhibited high levels
of methylation, and have been reported previously in as-
sociation with CIMP [17]. Interestingly, serum levels of
RASSF1A and DCR2 methylation were reported to have
prognostic importance [41,42]. The epigenetic inactiva-
tion of genes with such diverse tumor suppressive func-
tions as growth arrest (RASSF1A) and apoptosis (CASP8
A1 and DCR2) may be requisite for neuroblastoma
tumorigenesis. In this regard it is interesting to observe
that promoter hypermethylation in the same genes oc-
curred in neuroblastoma cell lines, a phenomenon also
observed by Hoebeeck et al. [9]. In the current study the
relative methylation patterns were similar between cell
lines and primary tumors (Table 2): for TSGs in which
high levels of methylation were observed in cell lines,
methylation was abundant even amongst the tumor
samples. An appealing prospect from this is that neuro-
blastoma cell lines may be scanned for putative methyla-
tion in TSGs, perhaps using array techniques, in order
to identify the most relevant TSGs in neuroblastomas.
In an approach by Carén et al. [34] that utilized chem-
ical de-methylation of cell lines in combination with ex-
pression arrays a number of genes were identified as
differentially methylated in neuroblastomas. Interest-
ingly, no bona fide TSGs were identified. Several studies
now confirm the presence of gene hypermethylation in
neuroblastoma. While this is an important observation
the cause-effect relationship between tumorous neuro-
blastoma and gene hypermethylation should be further
investigated to facilitate improved treatment approaches.Conclusions
This study provides a quantitative corroboration of pre-
vious observations that DNA methylation, in a subset of
tumor suppressor genes, is a common event in neuro-
blastomas; and that it is associated with adverse out-
come of the disease. The findings demonstrate a
comparable involvement of methylation instability in
neuroblastoma tumors and neuroblastoma models, and
support an advancement of therapeutic strategies that
include the use of demethylating agents to counter TSG
silencing in this tumor type.Materials and methods
Ethics statement
The thirty-eight samples of neuroblastoma/ganglioneur-
oma studied were obtained from patients operated at the
Karolinska University Hospital. All samples were initially
collected with informed verbal consent from patients or
their legal guardians as documented in the patient's
medical journal. The collection and subsequent study of
the tissue material has been approved by the Karolinska
Institutet/Karolinska University Hospital Research Ethics
Committee.
Cell lines
Seven neuroblastoma cell lines were included in the
study: SK-N-DZ, SK-N-SH, SK-N-BE, SK-N-FI, SK-N-
AS, IMR-32, and SH-SY-5Y. Cells were grown as previ-
ously described [43].
Patients and tumor samples
A total of 38 primary tumors from 38 patients were
studied (case no 1–38). Clinical details and tumor char-
acteristics have been previously published for all cases
[44]. The tumor panel includes 35 neuroblastomas and 3
ganglioneuromas diagnosed between 0 m and 145 m
of age. Information for MYCN amplification and 1p
loss have been previously reported [44]. Results for
NORE1A methylation in tumors have been previously
published [44].
Non-tumor controls
DNA from histopathologically evaluated non-tumoral,
healthy adrenal medulla (N1-N4) was acquired from
Clinomics Biosciences, Inc. (Watervliet, NY, USA) [45].
The neural crest-derived cells of this healthy adrenal
medullary material came from adult individuals, and
represents the closest possible analogy to the neural
crest-derived cells that comprise neuroblastomas. For the
validation of individual pyrosequencing assays methylated
human DNA was purchased from Millipore/Chemicon
(Billerica, MA, USA) and used as positive control, while
normal lymphocyte DNA served as negative control.
Serial dilutions were made between in vitro methylated
DNA and unmethylated DNA and analyzed by Pyrose-
quencing to assess potential PCR bias towards either the
methylated or the unmethylated form. This was done for
all in-house designed Pyrosequencing assays (Additional
file 3: Table S3) employing ratios of 100%, 75% 50% 25%
and 0% of methylated vs. unmethylated DNA.
Extraction of DNA
Tissues were immediately snap frozen in liquid nitrogen
upon surgical removal. DNA extraction from primary
tumor samples and neuroblastoma cell lines was carried
out either by means of a standard phenol-chloroform
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gDNA Mini Tissue Kit (Invitrogen/Life Technologies
Corporation, Carlsbad, CA). A NanoDrop Spectropho-
tometer (ND-1000) was used to quantify the DNA.Detection of promoter methylation
Promoter methylation was quantified by Pyrosequencing
for 14 TSGs in tumors, cell-lines, reference samples, and
controls. 500 ng of each DNA sample was bisulfite treated
using the EZ DNA Methylation Gold Kit (Zymo Research,
Orange, CA, USA) and 25–50 ng was subsequently ampli-
fied in each gene-specific PCR reaction containing the fol-
lowing reagents: 0.2 mM of each primer (Additional file 3:
Table S3), 0.2 mM dNTPs, 1.6 units of HotStarTaq, and
10x PCR buffer (QIAGEN) in a final volume of 50 μl. The
reaction for DCR2 contained additional MgCl2 (QIAGEN)
in a final concentration of 3.0 mM. PCR conditions were:
95°C for 15 minutes then cycled 45 times at 95°C for 20
seconds, a gene-specific annealing temperature (Additional
file 3: Table S3) for 20 seconds and 72°C for 20 seconds,
followed by an extension at 72°C for 10 minutes. PCR was
followed by Pyrosequencing using specific sequencing pri-
mers (Additional file 3: Table S3) in either a Biotage
PSQTM 96MA Pyrosequencer or in a Biotage PyroMarkTM
Q24 Pyrosequencer. Methylation of LINE-1 repeat ele-
ments were analyzed as a measurement of global methyla-
tion levels using previously described methodology [24].
The standard operating procedure for performing pyrose-
quencing includes an internal control against incomplete
bisulfite conversion: The nucleotide dispensation order is
programmed in such a way that C nucleotides are dis-
pensed where the sequence contains a non-CpG cytosine.
If the bisulfite treatment is consummate, all of these Cs
have been converted to Ts, and there is no incorporation
of the dispensed C nucleotide. Our assays contained such
internal controls, and accordingly full bisulfite conversion
was ascertained in all samples.Statistical analysis
All calculations were performed in Microsoft Excel 2003
SP3 and in the STATISTICA data analysis software,
v. 7.0. P values ≤ 0.05 were considered significant. Only
genes that displayed methylation above the cut-off levels
were considered for statistical analysis. To gauge methy-
lation as a continuous variable in multiple promoters,
Z-scores were calculated for each gene according to the
formula: (Mean of the CpG methylation density of the
given promoter for each sample – mean of methylation
density for that promoter in the tumor panel)/SD of that
methylation density. A mean between Z-scores for all
assessed TSG promoters was calculated for each sample,
giving an overall methylation score used for comparison
between samples. Mean Z-scores for LINE-1 methylationwere also calculated. Z-scores and clinical/genetic fea-
tures (age, stage, high risk therapy, MYCN amplification,
1p loss, and outcome) were compared statistically in the
STATISTICA 8.0 software (Statsoft Inc., Tulsa, OK,
USA). We used Fischer’s exact test to compare categor-
ical variables; Mann–Whitney U-test and Kruskal-Wallis
one-way analysis of variance were used to analyze
groups of continuous data; and correlations between
continuous data were assessed using Spearman Rank
Order correlations. Patients were divided into two
groups based on whether their average Z-score was
higher or lower than the median of the Z-score average
for the methylated genes. The groups were compared by
log-rank test; results were illustrated using Kaplan-Meier
plots. Two patients with undetermined cause of death
were excluded from these calculations.
Additional files
Additional file 1: Table S1. Methylation densities for hypermethylated
genes in primary tumors.
Additional file 2: Table S2. Methylation densities in primary tumors for
genes without promoter hypermethylation involvement.
Additional file 3: Table S3. Details of Pyrosequencing assays.
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